Lilly publishes updated list prices for its incretin portfolio

Eli Lilly's public pricing pages now show updated list prices for its three main incretin medicines, each citing wholesale acquisition cost data from AnalySource accessed on January 1, 2026 ^[1][2][3].

Mounjaro (tirzepatide), approved for type 2 diabetes, carries a list price of $1,112.16 per fill, with one fill defined as a month's supply of four pens ^[1]. Zepbound (tirzepatide), the obesity version of the same molecule, is listed at a range of $499 to $1,086.37 per fill, where a monthly supply is defined as 28 days ^[2]. Trulicity (dulaglutide), Lilly's older weekly GLP-1 for type 2 diabetes, is listed at $1,006.93 per month, also defined as four pens ^[3].

What list price actually means

All three pages carry the same footnote: list price, also called wholesale acquisition cost or WAC, is the price at which Lilly sells its products to wholesalers ^[1][2][3]. That is not what shows up at the pharmacy counter. Lilly says what patients pay "will largely depend on the out-of-pocket costs set by their insurance provider, pharmacy charges, and/or discounts or financial assistance that may be available" ^[1][2][3].

The Zepbound range is wider than a single number because of Lilly's cash-pay channel. The company lists direct-to-patient prices for a 4-count single-dose vial (0.5 mL) and a single-patient-use KwikPen (2.4 mL, 0.6 mL per dose) at $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 each for 10 mg, 12.5 mg and 15 mg ^[2]. Lilly notes that this direct-to-patient price is not the WAC, because the product at that price is only available for purchase by cash-paying patients ^[2].

For people with commercial drug insurance that covers Zepbound, Lilly says they may be eligible to pay as low as $25 for a one- or three-month supply of single-dose pens, with a month defined as 28 days and up to four single-dose pens ^[2]. Government beneficiaries are excluded, savings are subject to monthly and annual limits, and the company states plainly that the program "IS NOT INSURANCE" and can be changed or ended at any time without notice ^[2].

Mounjaro has a similar structure. Commercially insured patients may be eligible for the Mounjaro Savings Card program, but patients with Medicaid, Medicare, Medigap, DoD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program are not eligible ^[1]. For Mounjaro, Lilly says data on specific insurance plan pricing "is not yet available" and that it will share average patient out-of-pocket costs once they become available ^[1].

Trulicity is the one product where Lilly publishes actual out-of-pocket figures. Based on an internal analysis of HealthVerity real-world data covering January through December 2024, the company reports that about 40% of patients with employer or private individual coverage pay $0 per prescription and 90% pay less than $75; about 70% of Medicare patients pay $0 and 90% pay less than $47; and about 90% of Medicaid patients pay $0 ^[3].

Why it matters for patients

List prices set the starting point for a lot of downstream math. They influence what a plan counts toward a deductible, what a coinsurance percentage is calculated against, and what an uninsured person may be quoted before any discount program is applied. Someone early in a deductible year can be exposed to something close to the full list figure, while someone with a favorable plan design and a savings card may pay a small fraction of it.

The gap between the Mounjaro list price of $1,112.16 ^[1] and the Zepbound cash prices of $299 to $699 ^[2] is striking given that both products contain tirzepatide. The difference reflects how each is sold and to whom, not a difference in the molecule.

The Trulicity numbers are a useful reminder that list price and lived cost often diverge widely ^[3]. But those figures come from Lilly's own internal analysis of 2024 data accessed in September 2025 ^[3], and comparable out-of-pocket breakdowns are not published for Mounjaro or Zepbound.

What happens next

The pricing data behind all three pages was accessed January 1, 2026 ^[1][2][3]. The sources do not say whether these figures represent an increase, a decrease or no change from prior list prices, so the direction of any year-over-year move is not known from these pages alone. Lilly has said it will publish average patient out-of-pocket costs for Mounjaro when that data becomes available, without giving a date ^[1]. Savings program terms for both Mounjaro and Zepbound can be amended or terminated by Lilly at any time ^[1][2].